Routine liver cancer checks could extend lives below current screening thresholds for alcohol-related cirrhosis
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
A new study led by investigators from Mass General Brigham found routine liver cancer screening to be cost-effective and life-extending for individuals with alcohol-associated cirrhosis, even when their annual risk of developing liver cancer is less than half the risk level guiding current screening recommendations.
Results, published in Clinical Gastroenterology and Hepatology, underscore the value of routine surveillance for both patients who continue to drink and those who achieved abstinence.
Alcohol-associated cirrhosis is a late stage of liver disease caused by heavy drinking, where scar tissue replaces healthy tissue and impairs proper liver function. This condition significantly increases the risk of developing a common form of liver cancer known as hepatocellular carcinoma (HCC).
Since routine HCC screening—consisting of an ultrasound and blood test—can be costly and time-consuming, current guidelines only recommend it for individuals whose annual risk of developing HCC is above 1%.
That cutoff comes from older studies, mostly in people with viral hepatitis. Recent data show yearly liver cancer risk in alcohol-associated cirrhosis is often below 1%, so it has been unclear whether these patients should be screened routinely.
The new study revealed that biannual screening was beneficial and cost-effective for individuals with an annual HCC risk as low as 0.45%, despite the traditional surveillance threshold being set at 1%.
"Our study shows that the 1% benchmark for screening is out of date for this population. Screening with today's tests and treatments provides good value at a much lower level of risk, and guidelines should be updated to reflect that," said senior author Jagpreet Chhatwal, Ph.D., director of the Center for Health Technology Assessment at Mass General Brigham and associate professor of radiology at Harvard Medical School.
"Updating the evidence base used to define screening eligibility could help clinicians detect more cancers at an earlier, more treatable stage while using health care resources efficiently."
To determine whether current surveillance guidelines remain cost-effective and beneficial for patients with alcohol-associated cirrhosis, Chhatwal and colleagues used a mathematical model incorporating real-world screening data and clinical practices to simulate the trajectory of liver disease in 50 million hypothetical U.S. patients.
Health outcomes were measured in quality-adjusted life years, a standard measure for health economics. For every 100,000 patients, surveillance generated an estimated 2,083 additional life-years among active drinkers and 3,357 additional life-years among abstinent patients.
"A common worry is that screening may not help patients who continue to drink, because they face other serious health risks," said Ali Hajjar, Ph.D., first author of the study, a former postdoctoral fellow at Mass General Brigham Center for Health Technology Assessment and now an assistant professor at MBS College of Business and Entrepreneurship in Saudi Arabia.
"We found that screening was cost-effective in both patients who kept drinking and those who had stopped. Catching cancer earlier gives these patients access to treatments that can extend their lives, so decisions about screening should not depend on drinking status alone."
Publication details
Ali Hajjar et al., Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis, Clinical Gastroenterology and Hepatology (2026). DOI: 10.1016/j.cgh.2026.09.035
Journal information: Clinical Gastroenterology and Hepatology
Key medical concepts
Clinical categories
GastroenterologyOncology Provided by Mass General Brigham Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Routine liver cancer checks could extend lives below current screening thresholds for alcohol-related cirrhosis (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-routine-liver-cancer-current-screening.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.